Methods for detecting early cancer

• US 7,090,983 B1
• Filed: 09/08/2000
• Issued: 08/15/2006
• Est. Priority Date: 09/10/1999
• Status: Expired due to Term

• Current Assignee: Medical Therapies Limited
• Original Assignee: Takashi Muramatsu
• Inventors: Sakuma, Sadatoshi, Kumai, Hideshi, Okamoto, Kohji, Muramatsu, Takashi, Ikematsu, Shinya, Oda, Munehiro
• Primary Examiner(s): DENT, ALANA HARRIS
• Application Number:
  US10/070,569
• Time in Patent Office: 2,167 Days
• Field of Search: 435/4, 435/7.1, 435/7.21, 435/7.23, 435/7.92, 435/7.94, 435/7.93, 530/300, 530/350, 530/385, 530/386, 530/387.1, 530/387.7, 530/388.1, 436/63, 436/64, 436/86
• US Class Current: 435/7.1
• CPC Class Codes: G01N 2333/475 Assays involving growth factors
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

MK (midkine) was found to rise in the blood or urine of patients with various types of cancers at early stage. Based on this finding, a method for detecting early cancer, comprising the step of measuring MK in blood or urine was completed.

Claims

1. A method of screening for early cancer, comprising the steps of:

(a) measuring the level of full-length human midkine, or a fragment thereof, in a body fluid;

(b) comparing the measured level obtained in (a) to a control human midkine protein level of a healthy subject; and

(c) diagnosing the presence of early cancer, defined as stage 0 or stage I of the TNM classification, when the comparison of (b) indicates that the measured level is elevated as compared to the control level.

2. The method according to claim 1, wherein the early cancer is gastric cancer.

3. The method according to claim 2, wherein the gastric cancer is at stage I.

4. The method according to claim 1, wherein the early cancer is hepatocellular carcinoma.

5. The method according to claim 4, wherein the hepatocellular carcinoma is at stage I.

6. The method according to claim 1, wherein the early cancer is lung cancer.

7. The method according to claim 6, wherein the lung cancer is at stage I.

8. The method according to claim 1, wherein the body fluid is serum or urine.

12. The method according to claim 1, wherein human midkine levels are measured using a sandwich enzyme immunoassay that includes an avian anti-human midkine antibody.

9. A method of screening for early cancer comprising the steps of:

(a) contacting a body fluid with a pair of antibodies that specifically bind to full-length human midkine, or a fragment thereof, in a body fluid;

(b) comparing the level of binding between the antibodies and human midkine of (a) to a control binding level of a healthy subject; and

(c) diagnosing the presence of early cancer, defined as stage 0 or stage I of the TNM classification, when the comparison of (b) indicates that the measured level is elevated as compared to the control level.

10. A method for assessing cancer prognosis, comprising the steps of:

(a) measuring the level of full-length human midkine, or a fragment thereof, in a body fluid both before and after tumor treatment, comparing the level measured after treatment to a level measured before treatment, and

(b) correlating a difference in the measured levels to cancer prognosis, wherein a reduction in the measured level after treatment is indicative of successful treatment and positive prognosis.

11. The method according to claim 10, wherein the cancer is gastric cancer, hepatocellular carcinoma, or lung cancer.

13. The method according to claim 10, wherein human midkine levels are measured using a sandwich enzyme immunoassay that includes an avian anti-human midkine antibody.